| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Negotiation > Data Collection and Negotiations |
|
Main Subject - Data Collection and Negotiations
What is data? How does it impact a negotiation. How do you gather it? Data is the meat of preparation. Negotiators should t According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ake the time to fully prepare. If they do this, often as not they will be better prepared than the other person. As a resul ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in t, they will likely control the conversation and its outcome. Data is any information available about a given topic, pers lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. on, commodity or situation. Having the discipline to gather, assess and use this data makes the difference between negotiat here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ing and begging. Preparedness is the key to a successful negotiation. Data is readily available in the information age. Co d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro mputers, data bases, the Internet. newspaper archives, public libraries, even company historians all have a wealth of raw d ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ata. Knowing where to look and how to search are excellent tools to develop to help you be a better negotiator. Computers easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi and the Internet are great tools when searching for data that is in the public domain. This type of information may be ava nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ilable at the library, newspaper archives, from a title company, or off the Internet. It is difficult to refute hard data. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ That is why it is worth the extra effort to gather. It is also important to know what facts can be used against you. When y ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ou conduct fact-based research, be alert for related information that may be used against you. The search for data should b ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a e broad-based and inclusive. Being properly prepared takes away the element of surprise at the moment of confrontation. Wh dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod en you are investigating the person or persons you will be confronting seek the counsel of others who know the person, stud cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin y previous negotiation results with the person or his company, casually discuss the person with his peers. Never miss an op tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen portunity to discuss him with his secretary or assistant. Often a little casual conversation will reveal reams of valuable t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel information about how his day is going, his travel schedule and even pressures around the office. In days of old secretarie ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust s were guardians at the door. Today the roles have changed and that former loyalty may be lacking. With a little sleuthing y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products , there are usually some valuable insights available. As with data-based research, cast a wide net and collect as much info . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de rmation about the other person's interests, nature, and reputation as possible. You can use this collective pool of data to elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip talk about his hobbies and interests to build a relationship or use it to be on the alert for his known stylistic tactics. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Are You Dramatically Different? How To Resign From Your Current Accountancy Job
|